Cancer drug targets are now largely determined by mutations, rather than tumor tissue. This shift in focus has introduced new challenges for scientists identifying targets. First they must choose the right genomic datasets from disconnected sources; then make aggregate data comparable despite different platforms or analytical pipelines. Human data protection also adds layers of security and legal complexity. In this seminar, we will examine how to overcome these challenges and plan for validating potential targets at the preclinical stage.